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ABSTRACT OF THE THESIS 
 
Biochemical Alterations in the Extracellular Matrix 
in a Murine Model of Duchenne Muscular Dystrophy 
 
by 
 
Jesse Wei-lun Chin 
 
Master of Science in Physiological Science 
University of California, Los Angeles, 2017 
Professor Rachelle Hope Watson, Chair 
 
Duchenne muscular dystrophy (DMD) is characterized by progressive muscle 
degeneration due to the absence of the protein dystrophin, and the subsequent loss of the 
dystrophin-glycoprotein complex, resulting in inflammation, degeneration/regeneration, and a 
decrease in muscular strength and function. Although the extracellular matrix was previously 
thought only to provide structural support to resident cells, there is a growing body of evidence 
implicating it in cell signaling pathways that may negatively affect muscle regeneration. Despite 
the increasingly acknowledged importance of the matrix, there is still very little we know about 
how matrix composition may change in DMD. Therefore, we utilize mass spectrometry to 
quantify biochemical changes that occur in the extracellular matrix in a murine model of DMD. 
Identification of changes in the matrisome between dystrophic and normal muscle will allow for 
the identification of future therapeutic targets that may inform the development of successful 
therapies for DMD.  
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BACKGROUND 
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder that 
affects 1 in 5,000 boys [1]. Those affected are wheelchair reliant by their early teen years and 
have a life expectancy of approximately thirty years. DMD is characterized by progressive 
muscle degeneration due to the loss of the protein dystrophin, a part of the dystrophin-
glycoprotein complex (DGC). The DGC serves as an anchor between the cytoskeletal 
components of the muscle fiber and the surrounding extracellular matrix. The absence of 
dystrophin results in loss of the DGC, leading to contraction-induced damage of the sarcolemma 
that initially results in inflammation, followed by continuous cycles of degeneration and 
regeneration [2]. Over time, regenerative processes are unable to repair the chronic muscle 
damage, resulting in an accumulation of fat and fibrotic tissue in the muscle [2, 3]. This 
ultimately results in a loss of muscular strength and function. At late stages, cardiac and 
respiratory muscle functions are compromised [4]. 
Although there is currently no cure for DMD, several therapies are currently under 
investigation. These include gene therapies aimed at introducing a functional dystrophin gene to 
muscles throughout the body, as well as cell transplantations that attempt to introduce dystrophin 
positive cells to muscle [5]. However, these current treatments have had limited success and face 
several challenges. For gene therapy, the largest obstacle is determining how to package and 
deliver the large dystrophin gene [5]. For cellular therapies, limited myoblast migration and 
differentiation result only in local effects around the injection sites [5, 6].  
The limited success of current therapies necessitates a broader approach to the 
development of treatments for DMD, including looking at factors extrinsic to the muscle cell [7]. 
Although the extracellular matrix was previously thought of as merely a passive structure that 
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only provided structural support to resident cells, there is a growing body of evidence that 
implicate it in cell signaling pathways. The matrix has a significant role in controlling myoblast 
proliferation and differentiation [8]. Decorin, a matrix proteoglycan, inhibits myostatin activity 
which decreases fibrosis and increases muscle fiber regeneration by increasing myocyte 
proliferation and differentiation [9, 10]. Furthermore, other extracellular matrix factors are 
known to modulate intracellular signaling pathways, such as the TGF-β pathway that modulates 
cell proliferation and fibrosis [11].  Matrix components such as matrix metalloproteinase-9, 
integrin αVβ6, plasmin, and thrombospondin-1 have all been shown to activate latent TGF-β [12-
17]. Despite the prominent effects the extracellular matrix has on these signaling pathways, we 
still know very little about the relative abundance of these components in the dystrophic 
extracellular matrix. 
Interestingly, several of the genetic modifiers and markers of DMD were found to be 
components of the extracellular matrix, such as osteopontin, latent TGF-β binding protein 4, 
annexin A6, fibronectin, and lumican [18, 19]. In DMD, the increasingly fibrotic composition of 
the extracellular matrix is a result of chronic inflammation that leads to unregulated deposition of 
matrix proteins as well as the replacement of contractile muscle fibers with non-contractile tissue 
[2, 3]. The accumulation of matrix proteins also forms a physical barrier that may hamper 
accessibility to the resident cells for targeted therapies [3]. When this inflammation or fibrosis is 
reduced, improvements in the pathology have been observed. Inhibiting fibrinogen-driven 
inflammation in muscles reduced both the inflammatory process as well as muscle degeneration 
[20]. The inhibition of collagen synthesis by halofuginone reduced muscle fibrosis and improved 
dystrophic pathology [21].  
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This relationship between the matrix and its resident cells represents a dynamical and 
reciprocal relationship. Resident cells secrete and produce the surrounding extracellular matrix, 
and in turn, the matrix affects the activity of the resident cells by upregulating or downregulating 
their activity. These signaling cascades produced by the matrix are especially relevant in DMD. 
While it was previously assumed that the eventual decrease in muscle regeneration observed in 
DMD was a result of reduced satellite cell regeneration, it was recently shown that satellite cells 
from aged dystrophic muscle have the same regenerative ability as wild type satellite cells when 
transplanted into a wild type mouse [22]. Therefore, it is not just the loss of dystrophin and the 
DGC, but also the altered biochemical composition of the matrix that plays a major role in the 
reduced regeneration observed in DMD.  
Administering ECM components has already been found to improve DMD pathology. 
Biglycan is a matrix proteoglycan that controls sarcolemmal integrity by regulating components 
of the dystrophin-associated protein complex [23]. Like dystrophic mice, biglycan deficient mice 
have a sarcolemma that is leaky and susceptible to damage. Administering recombinant biglycan 
to dystrophic mice ameliorated several pathological markers of DMD with a resultant increase in 
muscle strength and myofiber size, decrease in the number of centrally located nuclei and 
decrease in the levels of creatine kinase in the blood [24]. Another potential therapeutic ECM 
target is laminin, an important protein in the basement membrane of the matrix that facilitates 
binding of the dystroglycan complex to the extracellular matrix [25]. Laminin-111 treatment of 
mdx mice improved the pathology by increasing muscle strength, sarcolemmal integrity, and 
resistance to fatigue, reduced inflammation, and reduced exercise-induced damage [6, 26]. When 
coupled to myoblast transplantation, laminin-111 treatment improved myoblast proliferation and 
migration compared to myoblast transplantation alone [6]. Coupling cellular therapies to targeted 
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changes in the biochemical composition of the matrix and its associated factors, or the matrisome 
[27], may then be a new treatment paradigm for DMD.  
Despite the increasingly acknowledged importance of the extracellular matrix in the 
regulation of muscle cell activity, there is still very little we know about the matrix in terms of its 
composition or how it changes in DMD. While the composition of collagen in the ECM has been 
well documented, other areas of the matrisome are not as well understood. Understanding these 
changes in the matrix will provide a greater picture of the signaling pathways that are affected in 
DMD. Therefore, we utilize mass spectrometry to understand the biochemical changes that occur 
in the extracellular matrix in a murine model of DMD, with an emphasis on the glycoproteins 
that serve as signaling molecules in the matrix. Utilizing two separate decellularization 
techniques, we hope to determine and compare suitable methods to enrich for extracellular 
matrix proteins so that they can be adequately identified through mass spectrometry. We 
hypothesize that the absence of dystrophin and the DGC drives biochemical changes in the 
dystrophic matrix by upregulating or downregulating proteins in the matrisome. Identification of 
the changes in the matrisome between dystrophic and normal muscle will provide future 
therapeutic targets that may improve the success of current cellular therapies.  
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CHAPTER 1: PROTEOMIC ANALYSIS OF THE ECM WITH TRANSVERSE 
SECTIONS 
 
Introduction 
 The extracellular matrix (ECM) makes up only a small fraction of skeletal muscle. To 
perform biochemical analysis of the ECM, it is necessary to remove any cellular material prior to 
analysis to avoid any differences being masked by the presence of cellular material. This chapter 
described the development of protocols to: 1) isolate ECM from skeletal muscle and, 2) prepare 
ECM samples for proteomic analysis using mass spectrometry. Using these protocols, we will 
investigate changes in the biochemical properties of the ECM in mdx mice (murine model of 
DMD) relative to healthy wild-type controls.  
 
Materials and Methods 
 
Animals 
 Wild-type (C57BL/6J) and mdx male mice were purchased from Jackson Laboratories 
(Bar Harbor, ME, USA).  Mice were maintained in the Terasaki Life Sciences Vivarium 
following guidelines established by the Institutional Animal Care and Use Committee at the 
University of California, Los Angeles (approval #2000-029-43) and approval for these studies 
was granted by the UCLA Animal Welfare Assurance (approval #A3196-01). All mice used in 
the study were 18-20 weeks old.   
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Determination of optimal decellularization time  
 
Tissue preparation 
Wild type (n=3) and mdx mice (n=3) were euthanized by administering an overdose of 
isofluorane followed by cervical dislocation. The left and right quadriceps of each mouse were 
dissected and frozen with liquid nitrogen. Our laboratory previously determined that 30 minutes 
was the optimal exposure time to 1% SDS to successfully decellularize 30µm muscle sections, as 
determined by the absence of cellular material and nuclear material following H&E and DAPI 
staining (unpublished). While this method is best for immunofluorescence analysis of matrix 
components, it is an inefficient preparation method for the large volume of tissue needed for 
proteomic analysis. In an effort to maintain uniform section thickness for decellularization, we 
chose to section tissue at the maximal thickness capability of our cryostat (200 µm). The 
quadriceps muscles were transversely sectioned into 200µm thick sections at -18°C with a Leica 
CM3050S Research Cryostat and stored at -80°C (Figure 1-1). 
 
Time series decellularization 
Decellularization was performed with 1% SDS for ninety minutes. Every ten minutes, the 
SDS solution was removed and saved, replaced with fresh 1% SDS, and the decellularization 
was allowed to continue. The SDS supernatant for each time point was spun down and the 
resultant pellet or gelatinous homogenate was collected and stored for analysis.  
 
Confirmation of decellularization 
SDS-PAGE analysis was used to detect the presence of proteins in each time fraction of  
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the time series decellularization. Twenty microliters from each time point were loaded with 
1XLSB (loading sample buffer), containing SDS, sucrose, tris-HCl – pH7.4, β-mercaptoethanol, 
and bromophenol blue, on to a 6% SDS-PAGE gel. Gels were cast using the Mini-PROTEAN 
Tetra Handcast System for 1.5mm thick gels by Bio-Rad (Hercules, CA). A 30% acrylamide/bis 
solution, 19:1 from Bio-Rad (Hercules, CA) was used for the polyacrylamide stacking and 
separating gels. Bands were visualized by staining with Coomassie Blue for thirty minutes, 
followed by an overnight incubation in destain buffer (30% methanol, 10% glacial acetic acid). 
Imaging was performed with an Epson Perfection V19 scanner. 
 
Determination of optimal decellularization time 
Gels were stained with Coomassie Blue to detect whether bands were present in each 
time fraction. The most prominent band typically occurs between 35 and 55kDa and most likely 
corresponds to actin. The presence of bands was presumed to be predominantly cellular material 
being removed from the matrix and ending up in the supernatant. The optimal decellularization 
time was defined as the time when no bands were detected by Coomassie Blue staining. 
 
Mass spectrometry 
 
Tissue preparation 
Four to five hundred milligrams of sectioned tissue per wild type and mdx sample were 
decellularized with 1% SDS at 50rpm for using the optimal time period as determined by the 
time series decellularization analysis. The samples were then rinsed in subsequent washes with 
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PBS, ddH2O, and finally PBS to remove any remaining cellular debris. The wet weight of the 
remaining insoluble pellet was measured before being frozen and stored at -80°C (Figure 1-2). 
 
Enzymatic digestion 
The digestion protocol utilizes an on-pellet digestion as previously described [28]. 
Samples were resolubilized with urea, reduced with dithiothreitol, and alkylated with  
iodoacetamide. Glycan residues were removed with PNGaseF from New England Biolabs 
(Ipswich, MA). Digestion was performed with Lys-C from Thermo Fischer Scientific (Waltham, 
MA) and trypsin from Thermo Fischer Scientific (Waltham, MA). The samples were spun down 
and the supernatant was collected for C18 tip cleanup.  
 
C18 tip cleanup 
 Digested peptides were desalted and concentrated using Pierce C18 tips from Thermo 
Fisher Scientific (Waltham, MA). The C18 tips were wetted with 50% acetonitrile and 
equilibrated with 0.1% trifluoroacetic acid before being loaded with sample. The tips were then 
washed with 0.1% trifluoroacetic acid/ 5% acetonitrile and the peptides were eluted with 60% 
acetonitrile. The samples were speed vacuumed to near complete dryness and stored at -80°C. 
 
Mass spectrometry 
Samples were submitted to the UCLA Proteome Research Center (PRC) for analysis. All 
analysis was performed utilizing their established data analysis pipeline. In short, peptides were 
fractionated online with a 75µm inner diameter fritted fused silica capillary column with a [3-
4µm] pulled electrospray tip packed in-house with 17cm of Luna C18(2) 3µm reversed phase 
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particles (Phenomonex) [29, 30]. An acetonitrile gradient was delivered through the column with 
the Dionex UltiMate™ 3000 ultra high pressure nanoflow liquid chromatography system 
(Thermo Fischer Scientific) to separate peptides via ultra-high pressure liquid chromatography. 
MS/MS spectra were produced with an Orbitrap Fusion Lumos (Thermo Fischer Scientific). 
Fragmentation spectra were searched against theoretical fragmentation spectra generated from a 
protein database consisting of all mouse ORFs using MS-GF+. The peptide identifications were 
then filtered at the peptide (q < 0.01) and protein level (q < 0.01) using decoy database-derived 
false discovery rates and the Percolator and Fido algorithms, respectively. Peptide-level 
quantitation was performed by generating MS1-level extracted ion chromatograms using the 
Skyline software suite and then assessing chromatogram quality using mProphet (q < 0.01). 
Peptide-level quantitation was further analyzed using the MSStats tool to model protein 
abundances and perform statistical comparisons between wild type and mdx samples.  
Protein name, gene name, uniport ID, p-value and fold change for all proteins with a 
significant change of at least log21 between mdx vs. wild type were compiled into a table. 
Extracellular matrix proteins were determined through lists published by the Matrisome Project 
[31] and compiled into a separate table. Matrix proteins were organized into the groups: 
collagens, glycoproteins, proteoglycans, ECM regulators, and ECM affiliated proteins.  
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Figure 1-1: Schematic diagram of time series decellularization. (a) Quadriceps were 
isolated from wild type and mdx mice. Tissues were transversely sectioned (200µm) and 
placed in their respective 50mL conical tubes. (b) Samples were decellularized with 1% SDS. 
Every ten minutes, the tube was spun down at 3000rpm, supernatant was removed, and 
placed back on rotator with fresh SDS. Fractions were later concentrated and run on a 6% 
SDS-PAGE gel to detect whether predicted muscle proteins were present in each time 
fraction. 
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Figure 1-2: Schematic diagram of proteomic analysis 
with transverse quadricep sections and SDS 
decellularization. (a) Quadriceps were isolated from wild 
type and mdx mice and sectioned into 200µm thick 
sections. Total sections from each mouse were placed in a 
respective 50mL conical tube. (b) Samples were 
decellularized with 1% SDS (wild type= 30 min, mdx= 70 
min), followed by a series of rinses in PBS and ddH2O. 
Following the last PBS rinse, the sample was spun down, 
the PBS discarded and the pellet was collected. (c) The 
isolated pellet was resolubilized and digested with 
PNGaseF, trypsin, and Lys-C. The resultant peptides were 
desalted and concentrated with C18 tips before being 
submitted for LC-MS/MS analysis. 
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Results 
 
Wild type and mdx sections decellularize at different rates 
 To determine the optimal time to decellularize wild type and mdx samples, we utilized a 
time series decellularization. Ten-minute supernatant fractions revealed different rates of 
decellularization between wild type and mdx (Figure 1-3). Wild type SDS rinses revealed intense 
bands in the ten and twenty minute fractions, with feint staining of bands in thirty and forty-
minute time fractions. These are presumably cellular proteins as matrix proteins are often 
resistant to SDS degradation, insoluble, and therefore unable to run through the gel. A noticeable 
band occurring between 35 and 55kDa is most likely actin and its gradual decrease in intensity 
suggests the removal of these cellular contaminants. No further bands were detected after forty 
minutes. Mdx sections displayed strongly stained bands in the ten, twenty, and thirty-minute time 
fractions. Diffuse staining was found in the forty-, fifty-, and sixty-minute fractions. No further 
bands were detected in time fractions after sixty minutes. These time series decellularizations 
help validate the time needed to remove the maximum amount of cellular material while still 
maintaining the matrix proteins. Previous findings by our lab have noted the susceptibility of the 
wild type matrix to degradation by prolonged SDS treatment. On the contrary, the mdx matrix 
appears to be more resilient and requires more prolonged SDS treatment for adequate removal of 
cellular material. Based on our findings, and to ensure equal removal of cellular material, we 
selected thirty minutes as the optimal decellularization time for wild type, and seventy minutes 
for mdx samples. 
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Figure 1-3: Wild type and mdx quadricep sections decellularize at different rates. Wild type 
(a) and mdx (b) transverse quadricep sections (200μm) were decellularized with fresh 1% SDS 
every ten minutes for two hours. The first nine of the ten minute fractions were concentrated and 
analyzed through SDS-PAGE with a 6% gel and Coomassie stained. No bands were detected in 
the SDS washes after forty minutes for wild type and sixty minutes for mdx. Molecular weight 
markers (kDa) are indicated on the left. 
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Decellularization yield 
To determine the decellularization yield, the wet weight of samples before and after 
decellularization was obtained (Table 1-1). While the average starting tissue weight for wild type 
samples was 404.6 mg, the average tissue remaining after decellularization was 25.9 mg, 
providing a yield of 6.4%. Due to fibrosis, mdx samples performed slightly better with an 
average pre-decellularization weight of 435.3 mg and a post- decellularization weight of 49.8 
mg, for a yield of 12.0%.  
 
Mass spectrometry detects significant changes in the mdx extracellular matrix 
 To determine the biochemical composition of the extracellular matrix, mass spectrometry 
was used to identify the digested peptides present in each sample. Although the samples were 
decellularized to remove the cellular material and enrich for matrix proteins, mass spectrometry 
analysis revealed that the decellularized matrix still retained many cellular proteins (Table 1-2). 
Most of these cellular proteins were of mitochondrial and cytoskeletal origin. Of the fifty-nine 
total identified proteins with a significant change between mdx vs. wild type, only twenty-five 
were matrisome or matrisome related proteins. These matrisome changes were from categories 
such as the collagens, glycoproteins, proteoglycans, regulators of the ECM, as well as ECM 
affiliated proteins (Table 1-3). The largest number of identified matrix changes came from the 
glycoproteins. While several types of collagen were identified, only collagen types I, III, and V 
were significantly upregulated in mdx. The only identified protein that was downregulated in 
mdx was EMILIN-3, a matrix glycoprotein. 
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Table 1-1: Pre- and post-decellularization wet weights 
WT Pre-decell (mg) Post-decell (mg) Yield (%) 
1 406.4 28.4 7.0 
2 403.9 15.1 3.7 
3 403.4 34.2 8.5 
Average 404.6 25.9 6.4 
 
mdx Pre-decell (mg) Post-decell (mg) Yield (%) 
1 507.2 29.1 5.7 
2 402.3 65.3 16.2 
3 396.5 55.1 13.9 
Average 435.3 49.8 12.0 
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Table 1-3: Identified matrix proteins with a significant change between mdx vs. wild type 
quadricep muscle 
Protein Gene Name Uniprot ID P-Value Fold Change 
Collagens 
    Collagen alpha-1(I) chain CO1A1_MOUSE P11087 8.85E-04 1.61 
Collagen alpha-2(V) chain CO5A2_MOUSE Q3U962 0.01 1.76 
Collagen alpha-1(V) chain CO5A1_MOUSE O88207 0.01 2.59 
Collagen alpha-1(III) chain CO3A1_MOUSE P08121 0.01 3.88 
     Glycoproteins 
    EMILIN-3 EMIL3_MOUSE P59900 0.01 -12.43 
Nidogen-2 NID2_MOUSE O88322 0.04 1.36 
Sushi repeat-containing protein SRPX2 SRPX2_MOUSE Q8R054 0.01 2.21 
Fibrinogen beta chain FIBB_MOUSE Q8K0E8 0.04 2.32 
Fibrinogen gamma chain FIBG_MOUSE Q8VCM7 0.04 2.41 
Fibronectin FINC_MOUSE P11276 0.01 2.78 
Extracellular matrix protein 1 ECM1_MOUSE Q61508 0.01 2.93 
EMILIN-2 EMIL2_MOUSE Q8K482 0.02 3.43 
Periostin POSTN_MOUSE Q62009 0.01 3.87 
Hemicentin-2 HMCN2_MOUSE A2AJ76 8.68E-04 4.14 
Vitronectin VTNC_MOUSE P29788 0.01 4.98 
Cartilage intermediate layer protein 1 CILP1_MOUSE Q66K08 6.42E-04 7.88 
Insulin-like growth factor-binding protein 7 IBP7_MOUSE Q61581 0.02 15.46 
     Proteoglycans 
    Biglycan PGS1_MOUSE P28653 0.04 1.87 
Bone marrow proteoglycan PRG2_MOUSE Q61878 0.02 6.08 
     ECM Regulators 
    Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2_MOUSE Q61703 0.01 2.52 
Kininogen-1 KNG1_MOUSE O08677 0.03 3.70 
Cathepsin B CATB_MOUSE P10605 0.03 12.27 
Plasminogen PLMN_MOUSE P20918 0.02 14.04 
Serine protease HTRA1 HTRA1_MOUSE Q9R118 0.01 17.12 
     ECM Affiliated 
    Annexin A4 ANXA4_MOUSE P97429 0.04 8.61 
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Discussion 
Through proteomics, many previously established matrisome changes were identified. 
These include the upregulation of collagen types I, III, V, periostin, and fibronectin in the mdx 
matrix [32-35]. While the increased abundance of these proteins has been well described, many 
less well known protein changes were also captured. Emilin-3 was the only matrisome 
component that was significantly downregulated in mdx mice. This matrix glycoprotein inhibits 
TGF-β signaling [36]. The TGF-β signaling pathway is involved in inflammation and is normally 
upregulated in response to skeletal muscle damage [37]. Therefore, downregulation of EMILIN-
3 in the mdx matrix would relieve the inhibition on the TGF- β1 pathway [36], and potentially 
increase inflammation and deposition of fibrotic tissue. TGF- β1 upregulation also reduces the 
regenerative capacity of satellite cells by inhibiting their proliferation and differentiation [38]. 
Therefore, the observed downregulation of EMILIN-3 in mdx mice may play a role in DMD 
pathology. 
There were also several proteins identified that have not been well described in the 
context of skeletal muscle. Extracellular matrix protein 1 (ECM1) is a matrix glycoprotein that 
binds to perlecan, a heperan sulfate proteoglycan that is an important component of the basement 
membrane through its role in cell proliferation and adhesion [39]. In skin, it is hypothesized that 
ECM1 acts as a “biological glue” that may interact with various growth factors and regulate the 
basement membrane [40, 41]. Mutations in ECM1 result in a disease known as lipoid proteinosis 
[40]. Of the many pathological features, notable ones include thickening of the basement 
membrane as well as easily damaged skin that leads to scarring [42]. It is hypothesized that the 
absence of ECM1 alters regulatory pathways that ultimately result in the overexpression of 
collagen type IV [42]. While we did not capture a change in collagen type IV in the current 
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analysis, it would be interesting to see whether the overexpression of ECM1 in mdx also results 
in reduced expression of collagen type IV in the dystrophic matrix. Whether this can be 
translated to the susceptibility of the sarcolemma to contraction-induced damage and resultant 
muscle fibrosis observed in DMD remains to be seen. 
Insulin-like growth factor binding protein-7 (IGFBP-7) is another matrix glycoprotein 
that is significantly upregulated in the mdx matrix. It belongs to the larger IGFBP family that 
binds to insulin-like growth factors (IGF) and modulates various signaling pathways by 
regulating IGF activity [43-45]. While IGFBP-7 is known to be secreted by myoblasts, its exact 
role in skeletal muscle is poorly understood. In breast cancer cells, IGFBP-7 inhibited IGF-1 
signaling and resulted in cellular apoptosis [46]. IGF-1 is especially relevant in the context of 
skeletal muscle as it is a major constituent of the IGF-1/AKT pathway that is involved with 
muscle growth [47]. If there is a similar mechanism in skeletal muscle, it may be possible that 
the significantly upregulated levels of IGFBP-7 in the mdx matrix also inhibits IGF-1 signaling 
and induces apoptosis of myocytes. Blocking IGFBP-7 expression may therefore be a potential 
therapeutic target for DMD.  
The role of hemicentin-2 in vertebrate skeletal muscle remains poorly understood. 
Hemicentin-2 is a glycoprotein that is part of the fibulin family [48]. In C. elegans and zebrafish, 
hemicentin is capable of binding to perlecan in the basement membrane and may therefore be 
involved in the adhesion of the basement membranes between tissues [48, 49]. However, the 
cause of the significant upregulation of hemicentin-2 in mdx is not as readily apparent. 
Although our initial screen of matrisome changes agrees with the previous literature, only 
twenty-five significant matrix changes were identified. This is a small fraction of the hundreds of 
proteins that exist in the extracellular matrix. Furthermore, the absence of laminin, perlecan, and 
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type IV collagen, major components of the basement membrane, asks the question of whether or 
not our protocol is sufficiently isolating and detecting matrix components [28]. Another 
challenge with the decellularization protocol is the drastically different decellularization times 
needed for wild type and mdx samples. It is plausible that the increased fibrosis observed in mdx 
samples may be hindering not only the removal of cellular material out of the matrix, but also the 
accessibility of the matrix to the digestive enzymes needed for mass spectrometry analysis and 
subsequent protein identification. Future sample preparations should involve a more rigorous 
disruption of the muscle to not only normalize the decellularization times between mdx and wild 
type, but also ensure that the proteins can be easily digested for mass spectrometry analysis. 
One of the biggest challenges with the current decellularization protocol is a poor 
decellularization yield. Wild type and mdx samples had an average decellularization yield of 
6.4% and 12.0% respectively due to a significant loss of tissue during the rinses to remove any 
remaining SDS and cellular debris. Furthermore, there was irreversible binding of the sample to 
the sides of the tubes used for decellularization which further lowered the decellularization yield. 
This was more pronounced for wild type rather than mdx samples. In addition, the increased 
fibrosis present in mdx mice correspondingly increased the yield. While low, this yield may be 
somewhat realistic as the extracellular matrix occupies only 10% of skeletal muscle by volume 
[50]. Furthermore, while collagen is the most abundant protein in the extracellular matrix, it only 
contributes 1-10% to the muscle dry weight [51-53]. This agrees with our yield data for wild 
type and mdx mice. However, the significant loss of decellularized tissue during the 
decellularization process needs to be addressed as the eventual goal of this protocol is to analyze 
limited quantities of human biopsies.   
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CHAPTER 2: PROTEOMIC ANALYSIS OF THE ECM WITH FRACTIONAL 
DECELLULARIZATION 
 
Introduction 
 Although our previous method allowed for the successful detection of extracellular 
matrix proteins, very few matrisome changes were identified relative to the 274 proteins known 
to comprise the murine core matrisome [31]. To improve the detection of matrisome changes and 
to improve the removal of cellular contaminants, we utilized a fractionation based approach, 
allowing for isolation of specific muscle components. In addition, we explored the efficacy of 
homogenizing tissues to determine whether decellularization rates could be normalized between 
samples. We hypothesized that these protocol changes would increase the number of ECM 
protein changes identified through mass spectrometry. 
 
Materials and Methods 
 
Determining the effect of tissue homogenization 
 
Tissue preparation 
Quadricep muscles from eighteen to twenty-week-old wild type (n=1) and mdx mice 
(n=1) were obtained. For the proposed experiments, 100-200 mg of tissue was taken for each 
sample. Each sample was then homogenized using a chilled mortar and pestle before being 
stored at -80°C (Figure 2-1). 
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Time series decellularization 
 To assess the decellularization pattern of homogenized tissues, a time series  
decellularization was performed as previously described (page 6). Fractions were concentrated 
using Centriprep centrifugal filter units from EMD Millipore (Billerica, MA).  
 
Confirmation of decellularization 
The samples were then analyzed on a 7.5% SDS-PAGE gel that was cast using the SE600 
Ruby Vertical Gel Unit from GE Healthcare Bio-Sciences (Pittsburgh, PA). A 7.5% separating/ 
4% stacking gel was utilized to allow for improved separation of proteins on the larger gel.  Fifty 
microliters from each time point were loaded with 1XLSB, and the gel was run overnight at 
50mV. Visualization of the bands was performed as established before (page 7).  
 
Mass spectrometry  
 
Tissue preparation 
Quadricep muscles from eighteen to twenty-week-old wild type (n=5) and mdx mice 
(n=5) were obtained. For the proposed experiments, 100-200 mg of tissue was taken for each 
sample. Each sample was then homogenized using a chilled mortar and pestle before being 
stored at -80°C (Figure 2-1). 
 
Fractional decellularization 
 The fractional decellularization protocol performed was based on a previously described 
protocol by Naba et al [27]. The modified protocol utilized the compartmental protein extraction 
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kit from EMD Millipore (Billerica, MA). Homogenized samples were subjected to a series of 
buffers to extract the following fractions: (total tissue (TT), cytosolic (C), nuclear (N), membrane 
(M), cytoskeletal (CS), and a pellet that was enriched for the extracellular matrix (E). Ten 
micrograms of the pellet were removed from each sample for subsequent digestion, C18 tip 
cleanup, and analysis by mass spectrometry as described previously (pages 6-8). 
 
Confirmation of decellularization 
 To determine whether the fractionated samples were adequately decellularized, the 
fractions were run on a 7.5% SDS-PAGE gel. Total tissue, cytosolic, nuclear, membrane, 
cytoskeletal fractions, and PBS rinses were mixed with 1x LSB containing 100mM DTT while 
the extracellular matrix fraction was mixed with 5x LSB containing 100mM DTT. Visualization 
of the bands was performed as established before (page 7). 
 
Western Blotting 
 Proteins separated via SDS-PAGE were transferred onto nitrocellulose paper and 
visualized with Ponceau S staining. Following the transfer, the post-transferred SDS gel was 
stained with Coomassie Blue to confirm the successful transfer of proteins. Because changes in 
laminin in the mdx matrix were not detected in the previous protocol, the presence of laminin 
was probed to determine if there was an actual significant change between wild type and mdx, or 
if laminin was completely absent in the samples. To visualize the presence of laminin in each 
fraction, the nitrocellulose paper was incubated with an anti-laminin primary antibody (L9393, 
Sigma-Aldrich, concentration 1:1000), followed by the secondary antibody (ab6721, abcam, 
concentration 1:2000).  
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Figure 2-1: Schematic diagram of proteomic 
analysis utilizing fractional decellularization. (a) To 
prepare tissues, quadriceps were isolated from wild 
type and mdx mice and homogenized with a mortar 
and pestle. The homogenate from each mouse were 
placed in a respective 50mL conical tube. (b) Samples 
were decellularized through exposure to a series of 
buffers and spun down between steps to remove 
proteins from various cellular compartments. (C: 
cytosolic, N: nuclear, M: membrane, CS: cytoskeletal, 
E: extracellular matrix). (c) The isolated ECM pellet 
was resolubilized and digested with PNGaseF, trypsin, 
and Lys-C. The resultant peptides were desalted and 
concentrated with C18 tips before being submitted for 
LC-MS/MS analysis. 
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Results 
 
Decellularization rate following homogenization 
 Time series decellularization of the homogenized tissue reveals that wild type and mdx 
muscles had a similar decellularization profile (Figure 2-2). Following SDS-PAGE and staining 
with Coomassie Blue, lightly stained bands were detected in both WT and mdx samples during 
the first twenty minutes of SDS rinses, with intense staining after fifty minutes. There is 
substantially more material loss at the later time points (fifty to seventy-minutes), which differs 
from the decellularization profile for sectioned tissues in which greater protein loss occurred 
during the first twenty-minutes. 
 
Fractional decellularization greatly improves decellularization yield 
The wet weight of samples before and after decellularization is presented in Table 2-1. 
Wild type samples had an average pre-decellularization (total tissue fraction) weight of 124 mg 
and a post-decellularization (extracellular matrix fraction) weight of 82mg for a decellularization 
yield of 66%. Mdx samples had an average pre-decellularization weight of 130 mg and a post-
decellularization weight of 84mg for a decellularization yield of 65%.  
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Figure 2-2: Homogenizing normalizes decellularization progress between wild type and 
mdx. Homogenized wild type (left) and mdx (right) samples were decellularized with fresh 1% 
SDS every ten minutes for seventy minutes. Ten-minute fractions were concentrated and 
analyzed through SDS-PAGE with a 7.5% gel. The bands were visualized with Coomassie Blue 
staining. Homogenizing improved decellularization by normalizing decellularization rates 
between wild type and mdx samples. Molecular weight markers (kDa) are indicated on the left. 
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Table 2-1: Pre- and post-decellularization wet weights 
WT Pre-decell (mg) Post-decell (mg) Yield (%) 
1 130 84 65 
2 130 89 69 
3 130 75 58 
4 130 82 63 
5 102 78 76 
Average 124 82 66 
    mdx Pre-decell (mg) Post-decell (mg) Yield (%) 
1 130 85 65 
2 130 85 65 
3 130 74 57 
4 130 86 66 
5 130 90 69 
Average 130 84 65 
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Compartmental fractionation decellularization isolates different muscle fractions 
 To confirm that the compartmental protein extraction kit successfully decellularized the 
samples, a 7.5% SDS-PAGE gel was run (Figure 2-3). Total tissue fractions (TT) revealed a 
large number of bands with particularly strong staining around 250 and 40 kDa. Cytosolic (C), 
nuclear (N), membrane (M), and cytoskeletal (CS) fractions display different band profiles, 
confirming that different distributions of proteins are eluted in each fraction. The extracellular 
matrix fraction (E) displayed only two prominent bands at 250 and 40 kDa. It was noted that 
only the soluble proteins were able to run through the SDS-PAGE gel. Because the extracellular 
matrix consists largely of insoluble proteins, a majority of these were trapped at the bottom of 
the well and unable to enter through the stacking and separating gels. The lack of bands in the 
matrix fractions suggests the removal of cellular debris through each of the earlier fractions. 
Furthermore, the decrease in band intensity of the 250 and 40kDa bands from the total tissue to 
the matrix fractions suggests an enrichment for the extracellular matrix and therefore suggests 
that decellularization occurred.  
 
Mass Spectrometry 
 One hundred total significant changes between mdx and wild type decellularized tissues 
were identified from mass spectrometry (Table 2-2). Of these total hits, only eleven were 
matrisome or matrisome-associated proteins (Table 2-3). Many of the cellular contaminants 
included contractile proteins such as myosin, as well as mitochondrial proteins. The largest 
group of identified proteins belonged to the glycoproteins. Laminin β1 and α4 were significantly 
upregulated in the mdx matrix compared to wild type. Thrombospondin-4, asporin, and lumican 
30 
 
were detected, something not observed in the previous protocol. Periostin, fibronectin, and 
cartilage intermediate protein 1 (CILP1) were identified as significantly upregulated in mdx.  
 
Figure 2-3: Compartmental protein extraction isolates muscle fractions. Mdx (left) and wild 
type (right) samples were decellularized utilizing EMD Millipore’s compartmental protein 
extraction kit. A series of buffers were used to extract cytosolic, nuclear, membrane, 
cytoskeletal, and extracellular matrix proteins from the total tissue extract. Protein fractions were 
analyzed through SDS-PAGE with a 7.5% gel. The bands were visualized with Coomassie 
Brilliant Blue staining. (L: ladder, TT: total tissue, C: cytosolic, N: nuclear, M: membrane, CS: 
cytoskeletal, E: extracellular matrix, R: PBS rinse). Wild type and mdx matrix fractions both 
showed a vast removal of proteins from the total tissue fraction, enriching for insoluble 
extracellular matrix proteins that are unable to run through the gel. Molecular weight markers 
(kDa) are indicated on the left. 
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Table 2-3: Identified matrix proteins with a significant change between mdx vs. wild type 
quadricep muscle 
Protein Gene Name Uniprot ID P-Value Fold Change 
Glycoproteins 
    
Laminin subunit beta-1 LAMB1_MOUSE P02469 0.00 1.65 
Thrombospondin-4 TSP4_MOUSE Q9Z1T2 0.00 5.07 
Laminin subunit alpha-4 LAMA4_MOUSE P97927 0.03 8.34 
Periostin POSTN_MOUSE Q62009 0.00 17.30 
Fibronectin FINC_MOUSE P11276 0.00 17.99 
Cartilage intermediate layer protein 1 CILP1_MOUSE Q66K08 0.00 21.64 
     
Proteoglycans 
    
Asporin ASPN_MOUSE Q99MQ4 0.02 1.28 
Lumican LUM_MOUSE P51885 0.03 2.48 
     
Matrisome-associated 
    
Annexin A2 ANXA2_MOUSE P07356 0.02 8.15 
Serpin B6 SPB6_MOUSE Q60854 0.01 14.35 
Annexin A11 ANX11_MOUSE P97384 0.00 15.04 
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Western Blotting 
 To determine the cause for the low number of changes detected by mass spectrometry, 
Western Blotting was performed on the fractionated samples. Not all of the bands present in each 
fraction were efficiently transferred to the nitrocellulose membrane (Figure 2-4). Ponceau S 
staining of the membrane and Coomassie staining of the post-transferred gel revealed less 
intense staining for bands greater than 100kDa and less than 35kDa. Bands of approximately 
250kDa were especially difficult to transfer to the membrane. One of the significant changes 
detected during mass spectrometry, laminin, was chosen to understand which fraction it eluted 
from during the fractionation protocol. Western Blotting showed that laminin was detected in 
every fraction for both wild type and mdx (Figure 2-5), with the exception of the membrane 
fraction for mdx which possibly resulted from an error in loading the original sample. 
Furthermore, there is a poor enrichment for laminin in the extracellular matrix fraction. Instead, 
it appears laminin is non-selectively removed at each step of the fractionation protocol and 
appears in the nuclear and cytoskeletal fractions just as prominently as the matrix fractions.   
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Figure 2-4: Not all proteins are efficiently transferred to the nitrocellulose membrane. (a) 
Mdx (left) and wild type (right) samples decellularized with EMD Millipore’s compartmental 
protein extraction kit, run through SDS-PAGE, and transferred onto nitrocellulose paper. 
Transferred bands were visualized with Ponceau S staining. (L: ladder, TT: total tissue, C: 
cytosolic, N: nuclear, M: membrane, CS: cytoskeletal, ECM: extracellular matrix, R: PBS rinse.) 
(b) The post-transferred gel was Coomassie stained to determine transfer efficiency. Bands 
greater than 100 kDa, especially at 250 kDa, and bands lower than 35 kDa were not completely 
transferred to the nitrocellulose membrane. Molecular weight markers (kDa) are indicated on the 
left. 
38 
 
 
 
 
Figure 2-5: Laminin is present in each fraction. Mdx (left) and wild type (right) samples were 
decellularized with EMD Millipore’s compartmental protein extraction kit, run through SDS-
PAGE, and transferred onto nitrocellulose paper. Laminin was present in every fraction for both 
mdx and wild type with the exception of the membrane fraction for mdx. Laminin, a matrisome 
protein, was especially present in the nuclear, cytoskeletal, and extracellular matrix fractions. 
Due to extensive laminin loss in fractions other than the matrix fraction, fractionation is a poor 
method for enrichment of laminin. L: ladder, TT: total tissue, C: cytosolic, N: nuclear, M: 
membrane, CS: cytoskeletal, ECM: extracellular matrix, R: PBS rinse. * represents possible 
loading error during SDS-PAGE. Molecular weight markers (kDa) are indicated on the left. 
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Discussion 
One of the advantages of the fractionation protocol was the use of homogenization. When 
compared to decellularizing sectioned tissue, decellularizing homogenized tissue increases the 
ability of SDS to remove proteins from the matrix over time. For a similar starting pre-
decellularization weight, both wild type and mdx ended up with similar post-decellularization 
weights, confirming that homogenizing tissues prior to decellularization normalizes the 
decellularization rates between wild type and mdx. Therefore, homogenization improved the 
treatment protocol by establishing a single time for decellularization and allowed a greater 
degree of consistency between samples.  
 Although it was expected that decellularization with the compartmental protein kit would 
increase the number of matrisome changes, mass spectrometry analysis of the extracellular 
matrix fraction produced fewer hits than with analysis of the decellularized sectioned tissues. Of 
the 100 total significant changes between mdx and wild type, only 11 were matrisome proteins. 
This is drastically different from the previous chapter where we identified 59 total significant 
changes between mdx and wild type, of which 25 were identified as components of the 
matrisome. While the previous protocol identified several collagens, the fractionation protocol 
identified no significant differences in collagens. Furthermore, several proteins identified before 
were absent from this round of mass spectrometry. Despite fractionating the samples, large 
amounts of cellular contaminates such as mitochondrial proteins and myosin still appeared in the 
matrix fractions.  
 Given the high tissue yield following the fractional decellularization protocol, we 
expected to detect many more matrix proteins. The yields for both wild type and mdx was 66% 
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and 65% respectively, were nearly eleven times greater for wild type and five times greater for 
mdx than the yields observed when decellularizing with SDS. However, these yields are higher 
than would be expected since the matrix is only 1-10% of the total tissue by dry weight. The high 
yield may be a result of insufficient decellularization which would explain the large number of 
muscle proteins changes and low number of matrisome changes. In addition, the fractionation 
protocol did not seem to result in the correct proteins being extracted in their appropriate cellular 
fractions. Laminin staining revealed laminin present not only in the matrix fraction, but in all the 
fractions. If other matrix proteins are being extracted at earlier fractions and are not fully retained 
in the extracellular matrix, it is not possible to accurately quantitate matrisome changes between 
mdx and wild type.  
Considering that glycoproteins make up a relatively small fraction of the matrisome 
compared to structural proteins such as collagen, the inability to retain matrix components 
through fractionation makes it even more difficult to detect these small changes. Using the same 
fractions produced by this protocol, other members of our lab have stained for various 
sarcolemmal and cytosolic proteins and have noted that these proteins of interest end up in more 
than just the fractions they are expected to be found in. The buffers in the compartmental protein 
extraction kit do not seem to be able to cleanly extract for proteins by compartment and 
fractionation is therefore not an effective method to enrich for extracellular matrix proteins. 
While Naba and colleagues [28] had success with the fractionation protocol, this may be due to 
the choice of tissues they used, carcinoma and diaphragm. These two tissues are very different 
from skeletal muscle and are expected to have much less contractile proteins. It may be 
unrealistic to sufficiently remove these cellular contaminants in skeletal muscle to unmask all of 
the biological changes that are occurring between mdx and wild type. Due to this difficulty, a 
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future direction may be to remove the cellular contaminants from the spectral data before 
running the statistical analysis. 
Despite these shortcomings, the fractionation protocol was still able to identify the 
upregulation of laminin, an important component of the basement membrane that we had 
previously not been able to detect, as a significant change between mdx and wild type. 
Furthermore, periostin and fibronectin showed up again as major changes in the mdx matrix. 
Another glycoprotein, cartilage intermediate protein 1 appeared as the largest change in the mdx 
matrix. While we observed this change in the previous mass spectrometry protocol, we had 
dismissed its importance, as it appeared to be a glycoprotein that was more relevant in 
chondrocytes. Although CILP1 is more thoroughly studied in the context of cartilage, it has been 
found to be expressed in other tissues such as heart and skeletal muscle [54].  In degenerative 
conditions such as aging and osteoarthritis, CILP1 expression can be induced by TGF-beta 
signaling in cartilaginous tissue, which subsequently inhibits IGF-1 signaling and reduces 
cellular proliferation [55]. Although TGF-beta signaling initially induces the expression of 
CILP1, high CILP1 levels in turn inhibit TGF-beta signaling in cardiac fibroblasts through a 
negative feedback loop and block their differentiation into myofibroblasts [56]. While CILP1 is 
constantly involved with general homeostasis in cartilaginous tissues, CILP1 is only expressed 
after injury in cardiac muscle [56]. The significant increase in CILP1 in the mdx matrix is 
therefore puzzling as high expression of CILP1 should reduce TGF-beta signaling and ameliorate 
the fibrosis observed [37]. Because myocardial infarction is an acute injury, the high levels of 
CILP1 in mdx may be due to dysregulation of the TGF-beta signaling cascade and negative 
feedback loop due to chronic inflammation and injury in DMD [56]. Further research into this 
altered cascade may provide clues to the cause of the aberrant signaling.         
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CONCLUSION 
 Through proteomic analysis of the extracellular matrix of dystrophic and wild type mice, 
we were able to identify several proteins that are upregulated and downregulated in the matrix in 
DMD. These not only captured previously established changes such as fibronectin, periostin, and 
various collagens, but also proteins that are not so well known in the context of DMD such as 
EMILIN-3, ECM1, CILP1, and HMCN1. We compared two protocols to decellularize and 
analyze the matrix through mass spectrometry. In the first method, we found that sectioning the 
tissues and decellularizing with SDS resulted in low decellularization yield. In the second 
method, homogenizing tissue and fractionation improved the decellularization yield but resulted 
in a greater number of cellular contaminants which obscured many matrisome changes. Future 
studies will aim to combine these two protocols, utilizing the homogenization from the 
fractionation protocol, but decellularizing with SDS instead of the fractionation protocol. While 
previous attempts in our lab have failed using homogenized tissue for SDS decellularization and 
subsequent mass spectrometry analysis, this is most likely due to improper times of 
decellularization that resulted in too much sample loss.  
 The importance of utilizing proteomics to study how the matrix changes in DMD is 
paramount as it allows a broader identification of proteins than would be possible through 
Western Blotting alone. Identification of these changes may elucidate additional biomarkers for 
DMD as well as the discovery of novel therapeutic targets. Future directions will examine: 1) 
whether human samples display similar matrisome changes as mdx, and 2) whether the 
inflammatory process and subsequent matrix remodeling by acute damage through cardiotoxin 
injections is different in mdx.  
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